Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Autor: Luft, Alexander V., Karaseva, Nina A., Kowalyszyn, Rubén Dario, Hernandez, Carlos Alberto, Csoszi, Tibor, De Vita, Ferdinando, Pfeiffer, Per, Sugimoto, Naotoshi, Kocsis, Judit, Csilla, Andràs, Bodoky, Gyorgy, Garnica Jaliffe, Georgina, Protsenko, Svetlana, Madi, Ayman, Wojcik, Elzbieta, Brenner, Baruch, Folprecht, Gunnar, Sarosiek, Tomasz, Peltola, Katriina Johanna, Bono, Peter, Ayala, Hubert, Aprile, Giuseppe, Gerardo, Cardellino Giovanni, Huitzil Melendez, Fidel David, Falcone, Alfredo, Di Costanzo, Francesco, Tehfe, Moustapha, Mineur, Laurent, García Alfonso, Pilar, Obermannova, Radka, Senellart, Hélène, Petty, Russell, Samuel, Leslie, Acs, Peter Istvan, Hussein, Maen Abdelkarim, Nechaeva, Marina N., Erdkamp, F.L.G., Won, Elizabeth, Bendell, Johanna Chock, Gallego Plazas, Javier, Lorenzen, Sylvie, Melichar, Bohuslav, Escudero, Miguel Angel, Pezet, Denis, Phelip, Jean-Marc, Kaen, Diego Lucas, Reeves, James A. Jr, Longo Muñoz, Federico, Madhusudan, Srinivasan, Barone, Carlo, Fein, Luis Enrique, Gomez Villanueva, Angel, Hebbar, Mohamed, Prausova, Jana, Visa Turmo, Laura, Vidal Barrull, Joana, Yilmaz, Mette Karen Nytoft, Beny, Alex, Van Laarhoven, H.M.W., DiCarlo, Brian Anthony, Esaki, Taito, Fujitani, Kazumasa, Geboes, Karen, Geva, Ravit, Kadowaki, Shigenori, Leong, Stephen, Machida, Nozomu, Raj, Moses Sundar, Ramirez Godinez, Francisco Javier, Ruzsa, Agnes, Ford, Hugo, Lawler, William E., Maisey, Nicolas Robert, Petera, Jiri, Shacham-Shmueli, Einat, Sinapi, Isabelle, Yamaguchi, Kensei, Hara, Hiroki, Beck, Joseph Thaddeus, Błasińska-Morawiec, Maria, Villalobos Valencia, Ricardo, Alcindor, Thierry, Bajaj, Madhuri, Berry, Scott, Gomez, Christina Maria, Dammrich, Daniel, Patel, Ravindranath, Taieb, Julien, Ten Tije, A.J., Burkes, Ronald L., Cabanillas, Fernando, Firdaus, Irfan, Chua, Cynthia Coo, Hironaka, Shuichi, Hofheinz, Ralf-Dieter, Lim, Howard J., Nordsmark, Marianne, Piko, Bela, Verma, Udit, Wadsley, Jonathan, Yukisawa, Seigo, Gutiérrez Delgado, Francisco, Denlinger, Crystal S., Kallio, Raija, Pikiel, Joanna, Wojcik-Tomaszewska, Joanna, Brezden-Masley, Christine, Jang, Raymond Woo-Jun, Pribylova, Jana, Sakai, Daisuke, Bartoli, Maria Alejandra, Cats, A., Grootscholten, M.I., Dichmann, Robert Andrew, Hool, Hugo, Shaib, Walid, Tsuji, Akihito, Van den Eynde, Marc, Velez-Cortez, Hector, Asmis, Timothy R., Fuchs, Charles S ^*, Shitara, Kohei, Di Bartolomeo, Maria, Lonardi, Sara, Al-Batran, Salah-Eddin, Van Cutsem, Eric, Ilson, David H, Alsina, Maria, Chau, Ian, Lacy, Jill, Ducreux, Michel, Mendez, Guillermo Ariel, Alavez, Alejandro Molina, Takahari, Daisuke, Mansoor, Wasat, Enzinger, Peter C, Gorbounova, Vera, Wainberg, Zev A, Hegewisch-Becker, Susanna, Ferry, David, Lin, Ji, Carlesi, Roberto, Das, Mayukh, Shah, Manish A

Publikováno v: In The Lancet Oncology March 2019 20(3):420-435

233P Treatment pattern and outcomes for the first two lines of chemotherapy in patients diagnosed with metastatic triple-negative breast cancer, results from the Dutch SONABRE Registry

Autor: Geurts, S.M.E., Ding, N., Meegdes, M., Erdkamp, F.L.G., Heijns, J.B., Tol, J., Vriens, B., Dercksen, W., Aaldering, K., Pepels, M., Winkel, L.V.D., Peters, N., van de Wouw, A., Teeuwen, N., De Boer, M., Tjan-Heijnen, V.C.G.

Publikováno v: In ESMO Open May 2023 8(1) Supplement 4

94MO The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy: DATA trial analysis

Autor: Lammers, S.W.M., Geurts, S.M.E., van Hellemond, I.E.G., Swinkels, A.C.P., Smorenburg, C.H., van der Sangen, M., Kroep, J.R., de Graaf, H., Honkoop, A.H., Erdkamp, F.L.G., de Roos, W.K., Linn, S.C., Imholz, A.L.T., Smidt, M.M., Vriens, I.J.H., Tjan-Heijnen, V.C.G.

Publikováno v: In ESMO Open May 2023 8(1) Supplement 4

The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2-advanced breast cancer patients: A study of the Dutch SONABRE Registry

Autor: Meegdes, M., Geurts, S.M.E., Erdkamp, F.L.G., Dercksen, M.W., Vriens, B.E.P.J., Aaldering, K.N.A., Pepels, M.J.A.E., Winkel, L.M.H., Teeuwen, N.J.A., Boer, M., Tjan-Heijnen, V.C.G.

Publikováno v: International Journal of Cancer, 150(1), 124-131. Wiley

In August 2017, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy have been reimbursed in the Netherlands for patients with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer (ABC). This study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::b81f8879dedca986be4f8505191aefee
https://cris.maastrichtuniversity.nl/en/publications/a81f5f0c-b8d0-4f0a-90be-f51e6e20c018

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

Autor: Tol, J., Koopman, M., Rodenburg, C.J., Cats, A., Creemers, G.J., Schrama, J.G., Erdkamp, F.L.G., Vos, A.H., Mol, L., Antonini, N.F., Punt, C.J.A. ^*

Publikováno v: In Annals of Oncology April 2008 19(4):734-738